{"id":334661,"date":"2026-11-02T11:15:12","date_gmt":"2026-11-02T05:45:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=334661"},"modified":"2026-11-02T11:15:12","modified_gmt":"2026-11-02T05:45:12","slug":"sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/","title":{"rendered":"Sun Pharma Q2 FY27 Results: Net Profit Falls 36% to Rs 1,989 Crore on Rs 1,269 Crore One-Time Charges, While Adjusted Profit Rises 1.4% and Revenue Climbs 12%"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Sun Pharma Q2 FY27: net profit Rs 1,988.5 cr, down 36.2%, on Rs 1,268.8 cr one-time charges. Adjusted profit Rs 3,162 cr, up 1.4%. Revenue up 11.9%. Stock Rs 1,769.90.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Sun Pharma Q2 results for FY27 show net profit down 36.2% to Rs 1,988.5 crore, but the fall is due to exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs. Adjusted profit was Rs 3,162 crore, up 1.4%, and revenue rose 11.9% to Rs 16,198.7 crore. Sun Pharma shares were at Rs 1,769.90 at 11:08 AM IST on 2 November 2026, down 0.44%.<\/p>\n<\/p><\/div>\n<p><strong>Sun Pharma Q2 results<\/strong> for FY27 look alarming at first glance, because reported profit fell 36%. The detail is more nuanced: the drop is caused by one-time charges, and underlying profit and revenue grew. This <strong>Sun Pharma Q2 results<\/strong> analysis breaks down the numbers, what each business did, the share price reaction and what to watch.<\/p>\n<p>The share price is as of 11:08 AM IST on 2 November 2026. Financials are from the company&#8217;s results of Friday, 30 October 2026.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=discover\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Sun_Pharma_Q2_FY27_Results_Key_Numbers\" title=\"Sun Pharma Q2 FY27 Results: Key Numbers\">Sun Pharma Q2 FY27 Results: Key Numbers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Why_Did_Sun_Pharmas_Profit_Fall_36\" title=\"Why Did Sun Pharma&#x27;s Profit Fall 36%?\">Why Did Sun Pharma&#x27;s Profit Fall 36%?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Business_Performance_India_US_and_Innovative_Medicines\" title=\"Business Performance: India, US and Innovative Medicines\">Business Performance: India, US and Innovative Medicines<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Sun_Pharma_Share_Price_Reaction\" title=\"Sun Pharma Share Price Reaction\">Sun Pharma Share Price Reaction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#What_to_Watch_Next_for_Sun_Pharma\" title=\"What to Watch Next for Sun Pharma\">What to Watch Next for Sun Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Frequently_Asked_Questions_on_Sun_Pharma_Q2_Results\" title=\"Frequently Asked Questions on Sun Pharma Q2 Results\">Frequently Asked Questions on Sun Pharma Q2 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#What_were_Sun_Pharmas_Q2_FY27_results\" title=\"What were Sun Pharma&#x27;s Q2 FY27 results?\">What were Sun Pharma&#x27;s Q2 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Why_did_Sun_Pharmas_profit_fall_in_Q2\" title=\"Why did Sun Pharma&#x27;s profit fall in Q2?\">Why did Sun Pharma&#x27;s profit fall in Q2?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#How_did_Sun_Pharmas_US_business_perform\" title=\"How did Sun Pharma&#x27;s US business perform?\">How did Sun Pharma&#x27;s US business perform?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#How_did_Sun_Pharmas_India_business_perform\" title=\"How did Sun Pharma&#x27;s India business perform?\">How did Sun Pharma&#x27;s India business perform?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#What_is_Sun_Pharmas_share_price_today\" title=\"What is Sun Pharma&#x27;s share price today?\">What is Sun Pharma&#x27;s share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#What_is_the_Organon_acquisition\" title=\"What is the Organon acquisition?\">What is the Organon acquisition?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Is_Sun_Pharma_stock_valued_fairly_after_the_results\" title=\"Is Sun Pharma stock valued fairly after the results?\">Is Sun Pharma stock valued fairly after the results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q2-fy27-results-profit-falls-36-percent-one-time-charges-adjusted-profit-share-price\/#Should_I_buy_Sun_Pharma_after_a_profit_fall\" title=\"Should I buy Sun Pharma after a profit fall?\">Should I buy Sun Pharma after a profit fall?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Q2_FY27_Results_Key_Numbers\"><\/span><strong>Sun Pharma Q2 FY27 Results: Key Numbers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Consolidated net profit<\/td>\n<td>Rs 1,988.5 crore<\/td>\n<td>Rs 3,118 crore<\/td>\n<td>Down 36.2%<\/td>\n<\/tr>\n<tr>\n<td>Adjusted net profit (before exceptionals)<\/td>\n<td>Rs 3,162 crore<\/td>\n<td>Not stated<\/td>\n<td>Up 1.4%<\/td>\n<\/tr>\n<tr>\n<td>Revenue from operations<\/td>\n<td>Rs 16,198.7 crore<\/td>\n<td>Rs 14,478.3 crore<\/td>\n<td>Up 11.9%<\/td>\n<\/tr>\n<tr>\n<td>Exceptional charges<\/td>\n<td>Rs 1,268.8 crore<\/td>\n<td>Not stated<\/td>\n<td>One-time<\/td>\n<\/tr>\n<tr>\n<td>EBITDA margin<\/td>\n<td>29.3%<\/td>\n<td>31.3%<\/td>\n<td>Lower<\/td>\n<\/tr>\n<tr>\n<td>US formulation sales<\/td>\n<td>$455 million<\/td>\n<td>Not stated<\/td>\n<td>Down 8.2%<\/td>\n<\/tr>\n<tr>\n<td>Global innovative medicines<\/td>\n<td>$356 million<\/td>\n<td>Not stated<\/td>\n<td>Up 6.9%<\/td>\n<\/tr>\n<tr>\n<td>India formulation sales<\/td>\n<td>Not stated<\/td>\n<td>Not stated<\/td>\n<td>Up 17.3%<\/td>\n<\/tr>\n<tr>\n<td>R&amp;D spend<\/td>\n<td>Rs 778.4 crore<\/td>\n<td>Not stated<\/td>\n<td>4.8% of sales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Source: Sun Pharma Q2 FY27 results, Business Standard, Moneycontrol, Upstox and InCred Money reports. Different reports round some figures slightly.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Did_Sun_Pharmas_Profit_Fall_36\"><\/span><strong>Why Did Sun Pharma&#x27;s Profit Fall 36%?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Sun Pharma profit<\/strong> decline is driven by <strong>exceptional charges<\/strong> of Rs 1,268.8 crore booked in the quarter, which include a US antitrust settlement and costs linked to the <strong>Organon acquisition<\/strong>. Excluding these items, adjusted net profit was Rs 3,162 crore, up 1.4%. Because one-time items do not recur, the market usually looks at the adjusted number, although the settlement and acquisition costs are real cash and strategic costs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Business_Performance_India_US_and_Innovative_Medicines\"><\/span><strong>Business Performance: India, US and Innovative Medicines<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In the <strong>Sun Pharma Q2 results<\/strong>, <strong>India formulation<\/strong> sales grew 17.3%, the strongest part of the quarter. <strong>US formulation sales<\/strong> fell 8.2% to $455 million, a drag on the margin and an area investors watch closely. Global innovative medicines grew 6.9% to $356 million and now make up 21.1% of sales, which supports Sun Pharma&#8217;s shift toward specialty products. The company filed 4 ANDAs and received approval for 3 during the quarter.<\/p>\n<p><strong>Sun Pharma profit<\/strong> quality shows in margins: EBITDA margin was 29.3% against 31.3% a year earlier, which shows the cost of the US pressure and higher spending, even though EBITDA grew about 5% to Rs 4,743 crore.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for pharma stocks and valuations<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Share_Price_Reaction\"><\/span><strong>Sun Pharma Share Price Reaction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Sun Pharma share price<\/strong> rose about 4% to Rs 1,833.30 in afternoon trade on 30 October after the results but closed at Rs 1,777.70, and is at Rs 1,769.90 today, down 0.44%. At this price Sun Pharma has a market cap of about Rs 4.27 lakh crore, a P\/E of about 38.8 against an industry P\/E of about 38.1, a return on equity of 13.79% and a dividend yield of 0.90%. The valuation is in line with the sector, so growth in the US and specialty portfolio has to justify it.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_Next_for_Sun_Pharma\"><\/span><strong>What to Watch Next for Sun Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>For the <strong>Sun Pharma share price<\/strong>, four things matter: whether US generic sales stabilise, how quickly specialty products scale, the integration cost and timeline of the Organon acquisition, and whether further legal settlements arise. Management commentary on the next two quarters will matter more than this quarter&#8217;s reported profit.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to follow Sun Pharma and pharma stocks on your watchlist.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Sun Pharma Q2 results<\/strong> show reported profit down 36% but adjusted profit up 1.4% and revenue up nearly 12%, with India strong and the US weak. The stock is priced in line with the sector, so the next trigger is evidence that specialty growth and the Organon deal can lift margins.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Sun_Pharma_Q2_Results\"><\/span><strong>Frequently Asked Questions on Sun Pharma Q2 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Sun_Pharmas_Q2_FY27_results\"><\/span><strong>What were Sun Pharma&#x27;s Q2 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma reported consolidated net profit of Rs 1,988.5 crore, down 36.2% from Rs 3,117.95 crore, and revenue from operations of Rs 16,198.7 crore, up 11.9%. Adjusted net profit excluding exceptional items was Rs 3,162 crore, up 1.4%. EBITDA margin was 29.3% against 31.3% a year earlier.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Sun_Pharmas_profit_fall_in_Q2\"><\/span><strong>Why did Sun Pharma&#x27;s profit fall in Q2?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Profit fell because of exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and costs for the Organon acquisition. Without these one-time items, adjusted net profit rose 1.4% to Rs 3,162 crore. The settlement and acquisition costs are real, but they are not part of regular operating earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Sun_Pharmas_US_business_perform\"><\/span><strong>How did Sun Pharma&#x27;s US business perform?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> US formulation sales fell 8.2% to $455 million in Q2 FY27. Pricing pressure on generics is a recurring issue, and the US is a key market for the company. Investors watch for stabilisation and for specialty product launches that can offset the decline in generics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Sun_Pharmas_India_business_perform\"><\/span><strong>How did Sun Pharma&#x27;s India business perform?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> India formulation sales grew 17.3% in Q2 FY27, making it the strongest part of the quarter. Growth in chronic therapies and the strength of Sun&#x27;s field force are typically cited drivers, but check the company&#x27;s presentation for the specific breakdown by therapy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_share_price_today\"><\/span><strong>What is Sun Pharma&#x27;s share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma traded at Rs 1,769.90 on the NSE at 11:08 AM IST on 2 November 2026, down Rs 7.80 or 0.44% from Rs 1,777.70. The day&#x27;s range is Rs 1,722 to Rs 1,776.20. The market cap is about Rs 4.27 lakh crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Organon_acquisition\"><\/span><strong>What is the Organon acquisition?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Business Standard reported that Sun Pharma&#x27;s exceptional charges include costs connected to the acquisition of Organon. Check Sun Pharma&#x27;s stock exchange filings for the deal&#x27;s size, structure and expected completion, as those details affect leverage, margins and the pace of its specialty business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Sun_Pharma_stock_valued_fairly_after_the_results\"><\/span><strong>Is Sun Pharma stock valued fairly after the results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At a P\/E of about 38.8 against an industry P\/E of about 38.1 and a return on equity of 13.79%, Sun Pharma is priced in line with its sector. Whether that is fair depends on specialty growth, US recovery and margin trends. Brokerage targets differ, so compare views before deciding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_buy_Sun_Pharma_after_a_profit_fall\"><\/span><strong>Should I buy Sun Pharma after a profit fall?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A profit fall due to one-time items is different from an operating decline, but the US weakness and lower margin are real concerns. Review adjusted earnings, management guidance and valuation before buying, and stagger purchases. This is not investment advice, so consult a SEBI-registered advisor.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What were Sun Pharma's Q2 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma reported consolidated net profit of Rs 1,988.5 crore, down 36.2% from Rs 3,117.95 crore, and revenue from operations of Rs 16,198.7 crore, up 11.9%. Adjusted net profit excluding exceptional items was Rs 3,162 crore, up 1.4%. EBITDA margin was 29.3% against 31.3% a year earlier.\"}},{\"@type\":\"Question\",\"name\":\"Why did Sun Pharma's profit fall in Q2?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Profit fell because of exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and costs for the Organon acquisition. Without these one-time items, adjusted net profit rose 1.4% to Rs 3,162 crore. The settlement and acquisition costs are real, but they are not part of regular operating earnings.\"}},{\"@type\":\"Question\",\"name\":\"How did Sun Pharma's US business perform?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"US formulation sales fell 8.2% to $455 million in Q2 FY27. Pricing pressure on generics is a recurring issue, and the US is a key market for the company. Investors watch for stabilisation and for specialty product launches that can offset the decline in generics.\"}},{\"@type\":\"Question\",\"name\":\"How did Sun Pharma's India business perform?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"India formulation sales grew 17.3% in Q2 FY27, making it the strongest part of the quarter. Growth in chronic therapies and the strength of Sun's field force are typically cited drivers, but check the company's presentation for the specific breakdown by therapy.\"}},{\"@type\":\"Question\",\"name\":\"What is Sun Pharma's share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma traded at Rs 1,769.90 on the NSE at 11:08 AM IST on 2 November 2026, down Rs 7.80 or 0.44% from Rs 1,777.70. The day's range is Rs 1,722 to Rs 1,776.20. The market cap is about Rs 4.27 lakh crore.\"}},{\"@type\":\"Question\",\"name\":\"What is the Organon acquisition?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Business Standard reported that Sun Pharma's exceptional charges include costs connected to the acquisition of Organon. Check Sun Pharma's stock exchange filings for the deal's size, structure and expected completion, as those details affect leverage, margins and the pace of its specialty business.\"}},{\"@type\":\"Question\",\"name\":\"Is Sun Pharma stock valued fairly after the results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"At a P\/E of about 38.8 against an industry P\/E of about 38.1 and a return on equity of 13.79%, Sun Pharma is priced in line with its sector. Whether that is fair depends on specialty growth, US recovery and margin trends. Brokerage targets differ, so compare views before deciding.\"}},{\"@type\":\"Question\",\"name\":\"Should I buy Sun Pharma after a profit fall?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"A profit fall due to one-time items is different from an operating decline, but the US weakness and lower margin are real concerns. Review adjusted earnings, management guidance and valuation before buying, and stagger purchases. This is not investment advice, so consult a SEBI-registered advisor.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharma Q2 results: profit fell 36% to Rs 1,989 crore on one-time charges, but adjusted profit rose 1.4% and revenue 12%. India strong, US weak. Share price and what to watch.<\/p>\n","protected":false},"author":35,"featured_media":334658,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[18957,1007,7038,627,18956,318],"class_list":["post-334661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results","tag-organon-acquisition","tag-pharma-stocks","tag-q2-fy27-results","tag-sun-pharma","tag-sun-pharma-q2-results","tag-sun-pharma-share-price"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["334658"],"rank_math_title":["Sun Pharma Q2 FY27: Profit Falls 36% on One-Time Charges"],"rank_math_description":["Sun Pharma Q2 FY27 results: profit down 36% to Rs 1,989 crore on Rs 1,269 crore one-time charges, adjusted profit up 1.4%, revenue up 12%. Share price and outlook."],"rank_math_focus_keyword":["Sun Pharma Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/sun-pharma-q2-fy27-results-net-profit-falls-36-to-rs-1-989-crore-on-rs-1-269.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/334661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=334661"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/334661\/revisions"}],"predecessor-version":[{"id":334662,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/334661\/revisions\/334662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/334658"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=334661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=334661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=334661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}